Frontiers in antibiotic alternatives for Clostridioides difficile infection

Area of Science:

• Microbiology and Infectious Diseases
• Gastroenterology

Background:

• Clostridioides difficile (C. difficile) is a bacterium causing antibiotic-associated diarrhea.
• Healthy gut microbiota protects against C. difficile infection (CDI).
• Disturbed microbiota allows C. difficile colonization, leading to severe symptoms and potential death.

Discussion:

• C. difficile exhibits natural resistance to most antibiotics, limiting current treatment options.
• The rising prevalence of CDI is exacerbated by antibiotic overuse and the post-antibiotic era.
• Developing alternative CDI treatments is a critical challenge for the scientific community.

Key Insights:

• Recent advances include natural products, drug repurposing, high-throughput screening, phage therapy, and fecal microbiota transplantation.
• Vaccine development, prebiotics, probiotics, and toxin antidotes are also emerging strategies.
• These diverse approaches target CDI pathology through multiple mechanisms.

Outlook:

• Gaps and concerns in current alternative CDI therapeutic development require further investigation.
• Preparing a diverse arsenal of alternative therapeutics is essential for future CDI epidemics.
• Prioritizing research and development of these novel treatments is crucial for public health.